Impact of Anemia on Hospitalization Time, Charges, and Mortality in Patients with Heart Failure

Although anemia is known to influence clinical outcomes in heart failure (HF) patients, little is known about its impact on economic outcomes. A retrospective analysis was performed to determine the impact of hemoglobin (Hb) level on hospital length of stay (LOS), total charges, and hospital mortali...

Full description

Saved in:
Bibliographic Details
Published in:Value in health 2004-07, Vol.7 (4), p.464-471
Main Authors: Nordyke, Robert J., Kim, John J., Goldberg, George A., Vendiola, Ruby, Batra, Deepika, McCamish, Mark, Thomasson, James W.
Format: Article
Language:English
Subjects:
Adolescent
Adult
Age Factors
Aged
Aged, 80 and over
Analysis of Variance
anemia
Anemia - blood
Anemia - complications
Anemia - economics
heart failure
Heart Failure - complications
Heart Failure - economics
Heart Failure - mortality
hemoglobin
Hemoglobins - analysis
Humans
Length of Stay
Middle Aged
Multivariate Analysis
Outcome Assessment (Health Care)
outcomes research
Retrospective Studies
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Although anemia is known to influence clinical outcomes in heart failure (HF) patients, little is known about its impact on economic outcomes. A retrospective analysis was performed to determine the impact of hemoglobin (Hb) level on hospital length of stay (LOS), total charges, and hospital mortality in HF patients. Claims data were drawn from 21 teaching and nonteaching hospitals for patients hospitalized between October 1, 2000 and September 30, 2001. The impact of Hb on LOS, charges, and hospital mortality was determined using multivariate analyses. Two-stage least squares regression methods were used to assess the potential endogeneity of the economic outcomes (LOS and total charges) and Hb level. Of the 8569 patients in the analysis, 40.2% had Hb < 12 g/dl and 73.8% were ≥ 70 years of age. Hemoglobin had significant independent effects on all three outcomes. A 1 g/dl increase in Hb was associated with a 5.1% reduction in LOS ( P < 0.001), a 4.3% decrease in charges ( P < 0.001), and an 8.7% reduction in mortality risk ( P < 0.001). The impact of Hb on all outcomes was greatest in younger HF patients. This analysis demonstrates that higher Hb is associated with reductions in LOS, charges, and mortality in hospitalized HF patients. Further clinical studies are necessary to validate the cost effectiveness of pharmacologic intervention in anemic HF patients and its impact on patient care.
ISSN:1098-3015
1524-4733
DOI:10.1111/j.1524-4733.2004.74009.x